Premium
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine
Author(s) -
Evans D. I. K.,
Jones Patricia H. Morris,
Morley C. J.
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197511)36:5<1547::aid-cncr2820360502>3.0.co;2-t
Subject(s) - daunorubicin , medicine , mercaptopurine , prednisolone , myeloid leukemia , cytosine , cytarabine , leukemia , complete remission , gastroenterology , myeloid , chemotherapy , dna , biology , genetics
Eighteen children with acute myeloid leukemia have been treated with a four‐drug protocol using cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine. The initial remission rate overall was 78%. Of 15 children who completed a week's treatment, i.e. one complete cycle, 14 entered complete remission (93%). The median survival was 7 months, and the median survival for those entering remission was 12 1/2 months.